Akshat Malik: Department of Head and Neck Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Dr. E Borges Road, Parel, Mumbai, 400012, India.
Burhanuddin N Qayyumi: Department of Head and Neck Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Dr. E Borges Road, Parel, Mumbai, 400012, India.
Manish Mair: Department of Head and Neck Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Dr. E Borges Road, Parel, Mumbai, 400012, India.
Hitesh Singhavi: Department of Head and Neck Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Dr. E Borges Road, Parel, Mumbai, 400012, India.
Yash Mathur: Department of Head and Neck Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Dr. E Borges Road, Parel, Mumbai, 400012, India.
Deepa Nair: Department of Head and Neck Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Dr. E Borges Road, Parel, Mumbai, 400012, India.
Sarbani Ghosh-Laskar: Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Dr. E Borges Road, Parel, Mumbai, 400012, India.
Jai Prakash Agrawal: Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Dr. E Borges Road, Parel, Mumbai, 400012, India.
Kumar Prabash: Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Dr. E Borges Road, Parel, Mumbai, 400012, India.
Pankaj Chaturvedi: Department of Head and Neck Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Dr. E Borges Road, Parel, Mumbai, 400012, India. chaturvedi.pankaj@gmail.com.
BACKGROUND: This study was undertaken to assess the effects of neo-adjuvant chemotherapy (NACT) on patients with head and neck squamous cell carcinoma (HNSCC) having advanced unresectable cervical nodal metastasis. METHODOLOGY: A retrospective cohort study was conducted to assess the response of unresectable nodes to NACT in a pragmatic manner. Patients were grouped according to the response noted and the treatment offered after chemotherapy. The median survival amongst the patients in these groups was compared. RESULTS: The study included 51 patients. Oral cavity was the commonest site (67.2%). Favourable nodal response was seen in 64.7% of the patients. Up to 87.9% of the nodal responders were amenable to curative intent therapy. The overall survival of patients undergoing surgery, definitive chemoradiotherapy, palliative chemotherapy and palliative radiotherapy was 24, 13, 10 and 9 months, respectively. CONCLUSION: NACT may be utilized in HNSCC with advanced inoperable nodal disease to make them amenable to definitive therapy.